IP Verse

Wuesthoff & Wuesthoff competitive analysis

Latest publications and patents of Wuesthoff & Wuesthoff New

Explore the latest publications and patents granted to Wuesthoff & Wuesthoff, showcasing their recent innovations and technological advancements.

Latest oppositions filed by Wuesthoff & Wuesthoff

Explore patent oppositions filed by Wuesthoff & Wuesthoff against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3689365
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKAug 6, 2025
EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025
EP3638243
Methods For Treating Myeloproliferative Neoplasm-Associated Myelofibrosis And AnemiaCELGENEMay 5, 2025
EP3490582
Methods And Compositions For Treating MyelofibrosisACCELERON PHARMAMar 10, 2025
EP4089071
Xylylene Diisocyanate Composition, Modified Xylylene Diisocyanate Composition, Polymerizable Composition, Resin, Molded Body, Optical Element, And LensMITSUI CHEMICALSFeb 12, 2025
EP3227447
Guide Rna With Chemical ModificationsAGILENTJan 14, 2025
EP3226887
Methods For Treating Myelodysplastic Syndromes And Sideroblastic AnemiasACCELERON PHARMADec 20, 2024
EP3460063
Methods And Compositions For The Targeted Modification Of A GenomeREGENERON PHARMACEUTICALSDec 12, 2024
EP3380121
Methods For Treating Eye DisordersACCELERON PHARMASep 18, 2024
EP3626270
New UseNOVARTISJul 10, 2024

Latest PTAB cases involving Wuesthoff & Wuesthoff

Discover the latest PTAB cases involving Wuesthoff & Wuesthoff, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Wuesthoff & Wuesthoff with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB33 - - - Highly Aggressive
CITY OF HOPE - 4 - - Non-Active
NOVARTIS6406 - 21Defensive
REGENERON PHARMACEUTICALS3893930Balanced